Phase II trial of vorinostat and gemtuzumab ozogamicin as induction and post-remission therapy in older adults with previously untreated acute myeloid leukemia

Histone deacetylase inhibitors such as vorinostat enhance gemtuzumab ozogamicin efficacy in vitro. We, therefore, investigated vorinostat+gemtuzumab ozogamicin for adults aged 60 years and over with untreated acute myeloid leukemia. We stratified patients into 2 groups (group 1: patients aged ≥70 ye...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Walter, Roland B., Medeiros, Bruno C., Powell, Bayard L., Schiffer, Charles A., Appelbaum, Frederick R., Estey, Elihu H.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ferrata Storti Foundation 2012
Gaiak:
Original Articles and Brief Reports
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3342977/
https://ncbi.nlm.nih.gov/pubmed/22133771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.055822
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak